Journal of Cardiac Failure
Volume 14, Issue 1 , Pages 1-5, February 2008

A Randomized, Controlled Trial of the Renal Effects of Ultrafiltration as Compared to Furosemide in Patients With Acute Decompensated Heart Failure

  • Hobart L. Rogers, PharmD

      Affiliations

    • University of Maryland School of Pharmacy, Baltimore, Maryland
  • ,
  • Joanne Marshall, BSN

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland
  • ,
  • Jeremy Bock, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland
  • ,
  • Thomas C. Dowling, PharmD, PhD

      Affiliations

    • University of Maryland School of Pharmacy, Baltimore, Maryland
  • ,
  • Erika Feller, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland
  • ,
  • Shawn Robinson, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland
  • ,
  • Stephen S. Gottlieb, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland
    • Baltimore Veterans Administration Medical Center, Baltimore, Maryland
    • Corresponding Author InformationReprint requests: Stephen Gottlieb, MD, Division of Cardiology, University of Maryland Medical Systems, 22 S. Greene St., Baltimore, MD 21201.

Received 20 June 2007; received in revised form 2 August 2007; accepted 8 September 2007. published online 03 January 2008.

Abstract 

Objectives

This study was designed to evaluate the consequences of ultrafiltration (UF) and standard intravenous diuretic (furosemide) therapy on glomerular filtration rate (GFR) and renal plasma flow in patients with acute decompensated heart failure.

Background

It has been hypothesized that treatment with diuretics may worsen renal function as the result of systemic neurohormonal activation and direct renal vascular effects. UF also removes fluid, but its actions on intrarenal hemodynamics, and therefore renal function, are unknown.

Methods

Patients hospitalized for acute decompensated heart failure with an ejection fraction less than 40% and two or more signs of hypervolemia were randomized to receive UF or intravenous diuretics. Urine output, GFR (as measured by iothalamate), and renal plasma flow (as measured by para-aminohippurate) were assessed before fluid removal and after 48 hours.

Results

Nineteen patients (59 ± 16 years, 68% were male) were randomized to receive UF (n = 9) or intravenous diuretics (n = 10). The change in GFR (−3.4 ± 7.7 mL/min vs. −3.6 ± 11.5 mL/min; P = .966), renal plasma flow (26.6 ± 62.7 mL/min vs. 16.1 ± 42.0 mL/min; P = .669), and filtration fraction (−6.9 ± 13.6 mL/min vs. −3.9 ± 13.6 mL/min; P = .644) after treatment were not significantly different between the UF and furosemide treatment groups, respectively. There was no significant difference in net 48-hour fluid removal between the groups (−3211 ± 2345 mL for UF and −2725 ± 2330 mL for furosemide, P = .682). UF removed 3666 ± 2402 mL. Urine output during 48 hours was significantly greater in the furosemide group (5786 ± 2587 mL) compared with the UF group (2286 ± 915 mL, P < .001).

Conclusions

During a 48-hour period, UF did not cause any significant differences in renal hemodynamics compared with the standard treatment of intravenous diuretics.

Key Words: Diuresis, renal function

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 All decisions regarding this manuscript were made by a guest editor.This study was funded by CHF Solutions, Inc., Minneapolis, Minnesota.

PII: S1071-9164(07)01071-8

doi:10.1016/j.cardfail.2007.09.007

Journal of Cardiac Failure
Volume 14, Issue 1 , Pages 1-5, February 2008